Eli Lilly has announced its acquisition of Centessa Pharmaceuticals for $38 per share, which could reach $47 with contingent value rights tied to regulatory milestones. This acquisition enhances Lilly's neuroscience and sleep disorder portfolio, solidifying its commitment to innovative therapies in the field. The deal is expected to close in Q3 2026, subject to approvals.
Eli Lilly has announced it will acquire Centessa Pharmaceuticals for $38.00 per share, totaling approximately $6.3 billion. This acquisition includes contingent value rights tied to FDA approvals of Centessa's promising sleep disorder treatments, which could enhance Lilly's portfolio and revenue stream in the neuroscience sector.